ClinicalTrials.gg
RecruitingNCT06377579Updated Nov 26, 2025

OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia

An observational study in AML, Adult, sponsored by French Innovative Leukemia Organisation. Recruiting at 21 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-26.

Sponsored by French Innovative Leukemia Organisation · Observational

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
250
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Leukemia, Myeloid, Acute by French Innovative Leukemia Organisation — 4 open to participants now, 7 under way, none of them phase 3. Leukemia, Myeloid, Acute · French Innovative Leukemia Organisation.

Started
2024
with 2 others
Observational
5 of 16
2 open now
Registered
14th of 16
by date

Among the 16 studies in Leukemia, Myeloid, Acute by French Innovative Leukemia Organisation, this one is one of 3 that started in 2024, is one of 5 observational ones, and was the 14th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

4 of the 16 studies in Leukemia, Myeloid, Acute by French Innovative Leukemia Organisation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Leukemia, Myeloid, Acute by French Innovative Leukemia Organisation, or all of them as a file.
02

Study summary

Mutations in IDH genes are found in numerous cancers and more specifically in acute myeloid leukemia (AML). These mutations target specific amino acids, at positions 140 or 172 of IDH2, and 132 of IDH1. Mutant IDH proteins acquire an abnormal enzymatic activity allowing them to convert α-ketoglutarate (αKG) into D-2 hydroxyglutarate (D-2HG), an oncometabolite which massively accumulates in IDH-mutated cells. At high levels, D-2HG behaves as a competitive inhibitor of αKG and affects the activity of Fe(II)/αKG-dependent dioxygenases. This enzymatic family is involved in a broad spectrum of pathways such as demethylation of histone (JHDM histone demethylases) or DNA (methylcytosine hydroxylases of the TET family). As a result, IDH-mutated cells show altered survival, motility, invasiveness and cell differentiation. In AML, IDH1 mutations might be present in 10-15% at diagnosis

Ivosidenib (IVO) a first-in-class, oral, irreversible inhibitor of mutant IDH1 has shown clinical activity as a single agent in studies involving patients with IDH1 mutated relapsed or refractory (R/R) AML and in front line settings. In phase II clinical trials, IVO yielded 30-35% of complete response rates both in frontline and R/R settings, with long lasting responses. Based on these results, the FDA (Food and Drug Agency) gave its approval for newly-diagnosed AML IDH1mut patients who are ≥ 75 years old or who have comorbidities and in R/R. However, European Medicines Agency (EMA)'s did not approved IVO due to lack of evidences to support the application. Agios Netherlands B.V. (the company that previously own the drug before Servier Laboratories) withdrew its EMA application. Nevertheless, IVO has been available in France through a compassionate use program (CUP), since February 2020 for R/R patients and March 2022 for first line treatment.

In this multicentric retrospective study, sponsor aim to evaluate the efficacy and safety of Ivo in two cohorts of IDH1mut AML patients treated within the CUP. The first cohort will concern patients treated in first line setting and the second cohort those treated in R/R disease. Results might provide new insights regarding IVO in real life settings and support signs of efficacy. This could provide new data for the haematologist community and for another appliance to grant EMA approval of IVO in the setting of R/R IDH1mut AML.

03

Conditions studied

  • AML, Adult
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients of 18 years old or more, with newly diagnosed or relapsed or refractory IDH1 mutated AML according to ELN 2022 and treated with IVO thanks to the CUP between the period 01/01/2017 to 01/08/2023, treated in French AML FILO or ALFA centers

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with IDH1 R132 mutated with newly diagnosed or (R/R) acute myeloid leukemia
  • Patient treated within French compassionate access program that have started the treatment between 01/01/2017 to 01/08/2023
  • patient treated by Ivosidenib received either as a monotherapy or in combination with other AML therapy (i.e. azacytidine, venetoclax)
  • Patient not included within IDH inhibitor clinical trial.

Exclusion criteria

Exclusion Criteria:

  • Patients who expressed their opposition to entered in the study
  • Patients who received IVO through a trial
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
250 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Groups and cohorts

  • AML in 1st line at inclusion
  • AML in R/R at inclusion
06

What researchers measure

Primary outcomes

  1. characterize the Overall survival (OS) in the both cohort : 1st line and Relapsed/Refractory (R/R)

    defined as the time from date of initiation of Ivosidebib to date of death due to any cause. Patients still alive or lost to follow up will be censored at the time they were last known to be alive

    Time frame: 6 months

Secondary outcomes

  1. characterize the composite response rate (CRc) at any time during follow-up, for the both cohort : 1st line and Relapsed/Refractory (R/R)

    CRc is defined as the sum of Complete remission (CR) + Complete remission with partial hematological recovery (CRh) + Complete remission with incomplete count recovery (CRi) + MLFS, according to ELN 2022 criteria

    Time frame: 6 months

  2. characterize the Event Free Survival (EFS) in both cohorts : 1st line and Relapsed/Refractory (R/R)

    defined as the time from initiation of Ivosidenib (IVO) to the date of treatment failure, hematologic relapse from Complete remission (CR)/Complete remission with partial hematological recovery (CRh)/ Complete remission with incomplete count recovery (CRi)/ Morphologic leukemia-free state (MLFS) or death from any cause, whichever occurs first; Treatment failure is defined as not achieving either CR, CRh,CRi or MLFS by day 180 from Ivo start

    Time frame: 6 months

  3. characterize the incidence and relatedness of serious adverse events (SAE), for patients treated by Ivosidenib, for both cohorts : 1st line and Relapsed/Refractory (R/R)

    description of grade 3/4 SAE and death according to CTCAE v5

    Time frame: 6 months

  4. describe the management of treatment by Ivosidenib in both cohorts : 1st line and Relapsed/Refractory (R/R)

    daily dose of Ivosidenib, description of Ivosidenib dose modification

    Time frame: 6 months

  5. describe the management of treatment by Ivosidenib in both cohorts : 1st line and Relapsed/Refractory (R/R)

    duration of treatment by Ivosidenib

    Time frame: 6 months

07

Study locations

6 of 21 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2024 to primary completion in Aug 2025, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2024
First posted
Apr 22, 2024
StartActual
Jul 31, 2024
Primary completionActual
Aug 30, 2025
CompletionEst.
Jun 1, 2026
Last update
Nov 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06377579
Lead sponsor
French Innovative Leukemia Organisation
Collaborators
Acute Leukemia French Association
Responsible party
Sponsor
First posted
Apr 22, 2024
Start date
Jul 31, 2024
Primary completion
Aug 30, 2025
Completion
Jun 1, 2026 (estimated)
Last update
Nov 26, 2025

Study contacts

Ariane MINEUR
Contact
ariane.mineur@chu-bordeaux.fr
+33 (0)5 57 62 31 08
Pierre PETERLIN, Dr
principal investigator · French Innovative Leukemia Organisation

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion